Alpha-methylacyl-CoA racemase expression is upregulated in gastric adenocarcinoma: a study of 249 cases.
Alpha-methylacyl-CoA racemase (AMACR [P504S]) is a mitochondrial and peroxisomal enzyme involved in beta-oxidation of dietary branched-chain fatty acids and their derivatives. Recent studies showed that AMACR is expressed in several neoplasms, including prostate and colon cancer. However, AMACR expression in gastric neoplasms has yet to be thoroughly investigated. Because AMACR overexpression in human solid tumors is a potential target for cancer treatment, we aimed to evaluate the expression of AMACR in a large cohort of patients with gastric adenocarcinoma. The study evaluated 249 primary gastric adenocarcinomas by immunohistochemistry. Nonneoplastic gastric tissue samples from various sites (antrum, body, fundus, and pylorus) were also examined. The immunopositivity of each sample was graded on a scale from 0 to 3 (0, no expression; 1, weak expression, 2, intermediate expression; 3, strong expression). We observed AMACR expression in 141 tumor cases: 44, 47, and 50 cases had weak, intermediate, and strong expression, respectively. Both intestinal and signet ring cell adenocarcinoma cases had overexpression of AMACR, however intestinal adenocarcinoma had significantly higher expression than did signet ring cell adenocarcinoma (p<0.05). Nonneoplastic gastric mucosa did not show AMACR expression. The results of our study demonstrate that AMACR expression is upregulated in gastric cancer, and suggest that further prospective studies to explore the potential role of AMACR as a therapeutic target for gastric cancer are warranted.
Truong
Camtu D
CD
Department of Pathology, The University of Texas M. D. Anderson Cancer Center Houston, TX, USA.
Li
Wei
W
Feng
Wei
W
Cagle
Philip
P
Khoury
Thaer
T
Alrawi
Sadir
S
Xie
Keping
K
Yao
James
J
Tan
Dongfeng
D
Pathology. 2006 Oct;38(5):426-32
17008281
Eur J Biochem. 1994 Jun 1;222(2):313-23
8020470
Hum Pathol. 2006 Jun;37(6):698-703
16733210
Br J Cancer. 2000 Nov;83(10):1394-400
11044367
APMIS. 2007 Jun;115(6):713-8
17550379
Oncology. 2006;71(3-4):246-50
17652945
Appl Immunohistochem Mol Morphol. 2006 Dec;14(4):411-6
17122637
Semin Oncol. 2005 Dec;32(6 Suppl 9):S90-3
16399441
J Lipid Res. 2000 Nov;41(11):1890-6
11060359
Am J Surg Pathol. 2002 Jul;26(7):926-31
12131161
Am J Surg Pathol. 2002 Jul;26(7):921-5
12131160
J Clin Pathol. 2003 Dec;56(12):892-7
14645345
Expert Rev Anticancer Ther. 2007 Oct;7(10):1379-93
17944564
Best Pract Res Clin Gastroenterol. 2007;21(6):965-81
18070698
Am J Clin Pathol. 2004 Aug;122(2):275-89
15323145
Hum Pathol. 2003 Aug;34(8):792-6
14506641
J Lipid Res. 2000 Nov;41(11):1752-9
11060344
Biochem Soc Trans. 2001 May;29(Pt 2):298-305
11356171
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42
17684125
Arch Pathol Lab Med. 2007 Oct;131(10):1555-60
17922592